



## PREFERRED DRUG LIST UPDATES

### Integrated (Title 19/21 SMI) and ACC, DD, ALTCS and DCS CHP

#### **Additions:**

- Dupixent Pen-Injector Soln 200mg/1.14ML (Prior Authorization)
- Dupixent Pen-Injector Soln 300mg/2ML (Prior Authorization)
- Dupixent Prefilled Syringe Soln 100mg/0.67ML (Prior Authorization)
- Dupixent Prefilled Syringe Soln 200mg/1.14ML (Prior Authorization)
- Dupixent Prefilled Syringe Soln 300mg/2ML (Prior Authorization)
- Eucrisa Oint 2% (Prior Authorization)

- Pimecrolimus Cream 1% (Prior Authorization)
- Berinert Kit 500unit (Prior Authorization)
- Cinryze Vial 500unit (Prior Authorization)
- Firazyr Syringe 30mg/3ML (Prior Authorization)
- Kalbitor Vial 10mg/ML (Prior Authorization)
- Orladeyo Cap 150mg (Prior Authorization)
- Symfi Lo Tab 400-300-300mg
- Symfi Tab 600-300-300mg
- Triumeq PD Soluble Tablet 60-5-30mg
- Vfend Suspension 40mg/ML

- Ella Tab 30mg (Quantity Limit)
- Tafluprost PF Ophthalmic Soln 0.0015%

#### **Removals:**

- Invirase Cap 200mg
- Invirase Tab 500mg
- Stavudine Cap 15mg
- Stavudine Cap 20mg
- Stavudine Cap 30mg
- Stavudine Cap 40mg
- Viracept Tab 250mg
- Viracept Tab 625mg
- Zioptan Ophthalmic Soln 0.0015%
- All Non-OneTouch Delica and Delica Plus Lancets and Lancet Devices

#### **Other Updates**

- None

### Behavioral Health (Non-Title 19/21)

#### **Additions:**

- None

#### **Removals:**

- None

#### **Other Updates**

- None

\*\* Drugs that are not on the formulary may be available via PA (prior authorization) \*\*

- For the complete preferred drug lists, please refer to the Mercy Care websites below
  - RBHA: <https://www.mercycareaz.org/providers/rbha-forproviders/pharmacy>
  - Mercy Care RBHA uses four preferred drug lists, depending on your member's eligibility.

- **Behavioral Health Preferred Drug List** : For members who qualify under Title 19/21 Non-SMI or as Non-Title 19/21 determined to have a serious mental illness (SMI), or Non-Title 19/21 children with a serious emotional disturbance (SED), Mercy Care RBHA fills only behavioral health medications.
- **Integrated Preferred Drug List** : For Title 19/21 SMI members, Mercy Care RBHA fills physical health and behavioral health medications.
- **Crisis Medication List** : For adults or children who are Non-Title 19/21 and Non-SMI who present in crisis at any of the facility-based psychiatric urgent care centers, detox facilities and/or access point in Maricopa, Gila or Pinal counties. The medications on this list will help stabilize an individual in crisis and bridge them to a follow-up outpatient appointment.
- **Substance Abuse Block Grant Medication List** : For Non-Title 19/21 members with SUDs and primary substance use and misuse.
  - ACC, DD, ALTCS and DCS CHP: <https://www.mercycareaz.org/providers/complecare-forproviders/pharmacy>

### 2023 HEDIS measures affecting Mental Health to monitor

The Healthcare Effectiveness Data and Information Set (HEDIS) is a widely used set of health care performance measures that is developed and maintained by the National Committee for Quality Assurance (NCQA). Highlighted here, are a few of the measures affecting mental health, to monitor.

Follow-Up After Hospitalization for Mental Illness (**FUH**) - The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider. Two rates are reported:

1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
2. The percentage of discharges for which the member received follow-up within 7 days after discharge.

Follow-Up After Emergency Department Visit for Mental Illness (**FUM**) - The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:

1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Depression Screening and Follow-Up for Adolescents and Adults (**DSF-E**) - The percentage of members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.

- Depression Screening. The percentage of members who were screened for clinical depression using a standardized instrument.
- Follow-Up on Positive Screen. The percentage of members who received follow-up care within 30 days of a positive depression screen finding.

Utilization of the Patient Health Questionnaire-9 (PHQ-9) to monitor depression symptoms for adolescents and adults (**DMS-E**) - The percentage of members 12 years of age and older with a diagnosis of major depression or dysthymia, who had an outpatient encounter with a PHQ-9 score present in their record in the same assessment period as the encounter.

Antidepressant Medication Management (**AMM**) - The percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported:

1. Effective Acute Phase Treatment. The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).
2. Effective Continuation Phase Treatment. The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).

Follow-Up Care for Children Prescribed ADHD Medication (ADD)- The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported:

1. Initiation Phase. The percentage of members 6–12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase.
2. Continuation and Maintenance (C&M) Phase. The percentage of members 6–12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)- The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported:

1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.
2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.
3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

Initiation and Engagement of Substance Use Disorder Treatment (IET)- The percentage of new substance use disorder (SUD) episodes that result in treatment initiation and engagement. Two rates are reported:

1. Initiation of SUD Treatment. The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visits or medication treatment within 14 days.
2. Engagement of SUD Treatment. The percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation.

**Take the time out to care for yourself and complete wellbeing, without you we will continue to experience a shortage of behavioral healthcare providers. You are the number one person of importance and do not forget that!**

Reminder for quicker determinations of a Prior Authorization use the ePA link for Our Providers: Please click [here to initiate an electronic prior authorization \(ePA\)](#) request

**References:**

1. <https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm>
2. <https://alert.psychnews.org/2022/12/more-americans-rate-their-mental-health.html>
3. <https://www.ncqa.org/hedis/measures/>

***This newsletter is brought to you by the Mercy Care Pharmacy Team. For questions, please email Fanny A Musto ([MustoF@mercycares.org](mailto:MustoF@mercycares.org)), Denise Volkov ([VolkovD@mercycares.org](mailto:VolkovD@mercycares.org)) or Trennette Gilbert ([gilbert@mercycares.org](mailto:gilbert@mercycares.org))***